Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $90.14 (market cap $41.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 8.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IEF | TVTX | |
|---|---|---|
Market Cap | $41.26B | $4.88B |
Volume | 12,778,487 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $67.52 |
52-Week Low | $88.92 | $26.79 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.71, up 0.31% with a bearish technical signal from moving averages and oscillators. The ETF shows flat support/resistance around $89-90. Recent dividend payments of $0.31-$0.33 provide income, but financial ratios are unavailable. Market sentiment reflects Treasury volatility amid rising yields and inflation concerns.
Outlook remains cautious due to persistent bond market pressures and macroeconomic uncertainty. Opportunities exist for income-focused investors via dividends, but risks include prolonged yield increases and geopolitical factors affecting fixed income. Monitor Federal Reserve policy shifts for directional cues.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
